# US 2009/0270339 A1 · Unit Dose Form of Glufosfamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270339 A1
- Document ID: US20090270339A1
- Status: Published application
- Kind: A1
- Application number: 12/303,551
- Filed: 2007-06-04
- Published: 2009-10-29
- Earliest claimed: 2006-06-06
- Inventors: Mike Li
- Web page: https://patentgrep.com/patent/US20090270339A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A lyophilized unit dose form containing about 2 g of glufosfamide is useful in treatment of cancer and other hyper-proliferative diseases.

## Claims

### Claim 1

A lyophilized unit dose form comprising at least about 2 g of glufosfamide API.

### Claim 2 (depends on 1)

The lyophilized unit dose form of claim 1 that contains about 2 g of glufosfamide API.

### Claim 3 (depends on 1)

The lyophilized unit dose form of claim 1 that is at least 95% pure.

### Claim 4 (depends on 1)

The lyophilized unit dose form of claim 1 containing no more that 0.5% water.

### Claim 5 (depends on 1)

The lyophilized unit dose form of claim 1 containing no more that 0.5% ifosfamide mustard.

### Claim 6 (depends on 1)

The lyophilized unit dose form of claim 1 containing no more that 0.5% glucose.

### Claim 7 (depends on 1)

The lyophilized unit dose form of claim 1 wherein the unit dose form is contained in a glass vial.

### Claim 8 (depends on 7)

The lyophilized unit dose form of claim 7, wherein the container is a glass vial having a volume of about 50 mL to about 100 mL; an inner diameter of about 3 cm to about 10 cm; and a length of about 10 cm to about 15 cm.

### Claim 9

A method of producing a lyophilized unit dose form comprising about 2 g of glufosfamide, the method comprising the steps of:
(a) annealing a solution of about 2 g glufosfamide and an aqueous solvent at a temperature of about Ta and for a time of about θa;
(b) conducting a first primary drying, at a vacuum of about V1, a temperature of about T1a, and for a time of about θ1a. the frozen mixture annealed in step (a);
(c) conducting a second primary drying, at a vacuum of about V1, a temperature of about T1b wherein T1b>T1a, and for a time of about θ1b, the frozen mixture first primary dried in step (b); and
(d) conducting a secondary drying, at a vacuum of about V2, a temperature of about T2 wherein T2>T1b, and for a time of about θ2, the frozen mixture second primary dried in step (c)
wherein, Ta is about 0° C. and θa is about 18 h; V1 is from about 120 microns to about 180 microns, T1a is about −20° C., θ1a is about 72 h, T1b is about 0° C., θ1b is about 38 h; and V2 is about 70 microns, T2 is about 25° C., and θ2 is about 24 h.

### Claim 10 (depends on 9)

The method of claim 9 for producing a lyophilized unit dose form containing about 2 g of glufosfamide.

### Claim 11

A method of treating cancer, said method comprising dissolving a lyophilized unit dose form comprising about 2 g of glufosfamide in a pharmaceutically acceptable solvent to yield a pharmaceutically acceptable solution of glufosfamide and administering the pharmaceutically acceptable solution of glufosfamide to a patient in need of such therapy.

### Claim 12 (depends on 11)

The method of claim 11 wherein the pharmaceutically acceptable solvent is saline.
